Clinical Trial Update: MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating MUC1-Activated T Cells for relapsed and resistant ovarian, fallopian tube, and primary peritoneal cancers; recruitment is ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• MUC1-Activated T-Cells

Snippet

Sponsor: Mayo Clinic | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Status: RECRUITING